Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Ítems similars

• Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
  per: Moran, AM, et al.
  Publicat: (2020)
• Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
  per: Shrimanker, R, et al.
  Publicat: (2017)
• Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
  per: Charlene Desaintjean, et al.
  Publicat: (2024-03-01)
• Glucocorticoids and mepolizumab in eosinophilic asthma.
  per: Bel, E, et al.
  Publicat: (2014)
• Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
  per: Andrea Portacci, et al.
  Publicat: (2023-10-01)